ARPEGGIO
(2025)Objective
To evaluate the safety, tolerability, and preliminary efficacy of scp776, a novel agent delivering IGF-1 to apoptotic cells, in acute ischemic stroke patients undergoing EVT
Study Summary
• Trend toward greater NIHSS improvement at day 7 (2.26 points vs placebo, p=0.066)
• 15% higher relative rate of functional independence (mRS 0–2) at 90 days
• 15% higher relative rate of functional independence (mRS 0–2) at 90 days
Intervention
scp776 (two IV doses, 24 hours apart) vs placebo in patients undergoing EVT
Inclusion Criteria
Acute ischemic stroke due to LVO within 24 hours of presentation, treated with EVT
Study Design
Arms: scp776 (dose-ranging) vs Placebo
Patients per Arm: 119 total (arm breakdown not specified)
Outcome
• Primary (safety): scp776 well-tolerated, comparable SAE rates to placebo
• NIHSS improvement at day 7: +2.26 points vs placebo (p=0.066)
• 90-day mRS 0–2: 15% higher relative rate with scp776
• Main AE: Hypoglycemia (manageable, consistent with mechanism)
• NIHSS improvement at day 7: +2.26 points vs placebo (p=0.066)
• 90-day mRS 0–2: 15% higher relative rate with scp776
• Main AE: Hypoglycemia (manageable, consistent with mechanism)